Dr. Piperdi on the Stimuvax Vaccine in Lung Cancer

Video

Bilal Piperdi, MD, from the Albert Einstein College of Medicine, discussed a trial looking at a vaccine in patients with lung cancer at the 8th Annual New York Lung Cancer Symposium®.

Bilal Piperdi, MD, Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Albert Einstein College of Medicine, discussed a trial looking at a vaccine in patients with lung cancer at the 8th Annual New York Lung Cancer Symposium®.

The vaccine, called Stimuvax, was compared with placebo as maintenance therapy following chemoradiation. The primary endpoint, overall survival, was not met in the intent-to-treat population.

In patients who received concurrent chemoradiation saw a 10-month survival benefit when treated with the vaccine. Piperdi says more research is planned in this space.

Related Videos
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD
Don S. Dizon, MD